Last Price$324.92.2%
Market Cap$175.6B
LTM ROIC - WACC
4.8%
5Y avg
10.6%
Drug Manufacturers - General industry
median
6.4%
Stock quality & Intrinsic value
6/10
0.4% undervalued
Amgen Inc. ROIC - WACC
Annual
Quarterly
LTM
Industry median
Company stand-alone
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROIC - WACC | 8.9% | 5.0% | 8.3% | 12.5% | 16.0% | 16.3% | 11.5% | 14.6% | 12.8% | 10.8% | 15.9% | 19.1% | 2.9% | 23.0% | 17.2% | 7.6% | 8.2% | 4.5% | 5.9% | 6.0% |
Overvalued or undervalued?
Check the intrinsic value for AMGN
and see if it's the right time to invest.
Amgen Inc. (AMGN) ROIC - WACC comparison analysis
General
LTM ROIC - WACC
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Amgen Inc.AMGN
4.8%
18.6%
(39.8%)
12.2%
Median Peer Set
8.2%
6.7%
(5.7%)
12.6%
Eli Lilly and CompanyLLY
56.1%
32.0%
102.4%
23.5%
Merck & Co., Inc.MRK
28.7%
1.4%
(97.6%)
0.6%
Gilead Sciences, Inc.GILD
12.1%
6.0%
(91.6%)
1.7%
Novartis AGNVS
10.8%
10.8%
(16.5%)
23.1%
Pfizer Inc.PFE
10.0%
8.8%
273.7%
12.6%
Bristol-Myers Squibb CompanyBMY
6.4%
7.3%
N/A
(18.5%)
Johnson & JohnsonJNJ
4.6%
4.3%
(57.9%)
15.8%
AbbVie Inc.ABBV
1.8%
3.7%
(11.4%)
7.6%
SanofiSNY
0.0%
(3.8%)
3.1%
12.6%
AstraZeneca PLCAZN
N/A
18.0%
135.9%
13.0%
AMGN key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 12,430.0 17.8% | 14,268.0 14.8% | 14,771.0 3.5% | 15,003.0 1.6% | 14,642.0 (2.4%) | 15,053.0 2.8% | 15,582.0 3.5% | 17,265.0 10.8% | 18,676.0 8.2% | 20,063.0 7.4% | 21,662.0 8.0% | 22,991.0 6.1% | 22,849.0 (0.6%) | 23,747.0 3.9% | 23,362.0 (1.6%) | 25,424.0 8.8% | 25,979.0 2.2% | 26,323.0 1.3% | 28,190.0 7.1% | 33,424.0 18.6% |
| Cost of Goods Sold (COGS) | 2,082.0 | 2,095.0 | 2,548.0 | 2,296.0 | 2,091.0 | 2,220.0 | 2,427.0 | 2,918.0 | 3,346.0 | 4,422.0 | 4,227.0 | 4,162.0 | 4,069.0 | 4,101.0 | 4,356.0 | 6,159.0 | 6,454.0 | 6,406.0 | 8,415.0 | 12,858.0 |
% margin | 10,348.0 83.3% | 12,173.0 85.3% | 12,223.0 82.7% | 12,707.0 84.7% | 12,551.0 85.7% | 12,833.0 85.3% | 13,155.0 84.4% | 14,347.0 83.1% | 15,330.0 82.1% | 15,641.0 78.0% | 17,435.0 80.5% | 18,829.0 81.9% | 18,780.0 82.2% | 19,646.0 82.7% | 19,006.0 81.4% | 19,265.0 75.8% | 19,525.0 75.2% | 19,917.0 75.7% | 19,775.0 70.1% | 20,566.0 61.5% |
| Operating Expenses | 5,500.0 | 7,102.0 | 7,444.0 | 7,493.0 | 7,045.0 | 7,288.0 | 8,843.0 | 8,770.0 | 9,463.0 | 9,450.0 | 8,965.0 | 9,035.0 | 8,807.0 | 9,383.0 | 9,332.0 | 10,126.0 | 10,381.0 | 10,351.0 | 11,878.0 | 13,308.0 |
| Research & Development Expenses (R&D) | 2,314.0 | 3,366.0 | 3,266.0 | 3,030.0 | 2,864.0 | 2,894.0 | 3,167.0 | 3,380.0 | 4,083.0 | 4,297.0 | 4,070.0 | 3,840.0 | 3,562.0 | 3,737.0 | 4,116.0 | 4,207.0 | 4,819.0 | 4,434.0 | 4,784.0 | 5,964.0 |
| Selling, General & Administrative Expenses (SG&A) | 2,790.0 | 3,366.0 | 3,361.0 | 3,789.0 | 3,820.0 | 3,983.0 | 4,486.0 | 4,801.0 | 5,184.0 | 4,699.0 | 4,846.0 | 5,062.0 | 4,870.0 | 5,332.0 | 5,150.0 | 5,730.0 | 5,368.0 | 5,414.0 | 6,179.0 | 7,096.0 |
% margin | 4,848.0 39.0% | 3,840.0 26.9% | 3,980.0 26.9% | 5,214.0 34.8% | 5,506.0 37.6% | 5,545.0 36.8% | 4,312.0 27.7% | 5,577.0 32.3% | 5,867.0 31.4% | 6,191.0 30.9% | 8,470.0 39.1% | 9,794.0 42.6% | 9,973.0 43.6% | 10,263.0 43.2% | 9,674.0 41.4% | 5,794.0 22.8% | 6,005.0 23.1% | 5,335.0 20.3% | 7,897.0 28.0% | 7,258.0 21.7% |
| Interest Income | 0.0 | 0.0 | 0.0 | 145.0 | 276.0 | 376.0 | 448.0 | 485.0 | 420.0 | 465.0 | 603.0 | 629.0 | 928.0 | 674.0 | 753.0 | 256.0 | 1,197.0 | 1,406.0 | 0.0 | 0.0 |
| Interest Expense | 29.0 | 2,282.0 | 2,136.0 | 344.0 | 578.0 | 604.0 | 610.0 | 1,053.0 | 1,022.0 | 1,071.0 | 1,095.0 | 1,260.0 | 1,304.0 | 1,392.0 | 1,289.0 | 1,262.0 | 1,197.0 | 1,406.0 | 2,875.0 | 3,155.0 |
| Pre-tax Income | 4,868.0 | 4,020.0 | 3,961.0 | 5,250.0 | 5,204.0 | 5,317.0 | 4,150.0 | 5,009.0 | 5,265.0 | 5,585.0 | 7,978.0 | 9,163.0 | 9,597.0 | 9,545.0 | 9,138.0 | 8,133.0 | 6,701.0 | 7,346.0 | 7,855.0 | 4,609.0 |
% effective tax rate | 1,194.0 24.5% | 1,070.0 26.6% | 795.0 20.1% | 1,054.0 20.1% | 599.0 11.5% | 690.0 13.0% | 467.0 11.3% | 664.0 13.3% | 184.0 3.5% | 427.0 7.6% | 1,039.0 13.0% | 1,441.0 15.7% | 7,618.0 79.4% | 1,151.0 12.1% | 1,296.0 14.2% | 869.0 10.7% | 808.0 12.1% | 794.0 10.8% | 1,138.0 14.5% | 519.0 11.3% |
% margin | 3,674.0 29.6% | 2,950.0 20.7% | 3,166.0 21.4% | 4,196.0 28.0% | 4,605.0 31.5% | 4,627.0 30.7% | 3,683.0 23.6% | 4,345.0 25.2% | 5,081.0 27.2% | 5,158.0 25.7% | 6,939.0 32.0% | 7,722.0 33.6% | 1,979.0 8.7% | 8,394.0 35.3% | 7,842.0 33.6% | 7,264.0 28.6% | 5,893.0 22.7% | 6,552.0 24.9% | 6,717.0 23.8% | 4,090.0 12.2% |
| EPS | 2.97 | 2.51 | 2.83 | 3.79 | 4.53 | 4.82 | 4.07 | 5.61 | 6.75 | 6.80 | 9.15 | 10.32 | 2.71 | 12.70 | 12.96 | 12.40 | 10.34 | 12.18 | 12.56 | 7.56 |
| Diluted EPS | 2.93 | 2.48 | 2.82 | 3.77 | 4.51 | 4.79 | 4.04 | 5.52 | 6.64 | 6.70 | 9.06 | 10.24 | 2.69 | 12.62 | 12.88 | 12.31 | 10.28 | 12.11 | 12.49 | 7.56 |
% margin | 5,689.0 45.8% | 7,265.0 50.9% | 5,981.0 40.5% | 6,639.0 44.3% | 6,580.0 44.9% | 6,671.0 44.3% | 5,054.0 32.4% | 6,356.0 36.8% | 7,391.0 39.6% | 8,747.0 43.6% | 11,132.0 51.4% | 11,937.0 51.9% | 12,804.0 56.0% | 12,883.0 54.3% | 12,633.0 54.1% | 12,929.0 50.9% | 12,542.0 48.3% | 12,093.0 45.9% | 14,702.0 52.2% | 15,686.0 46.9% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Amgen Inc.'s ROIC - WACC?
As of today, Microsoft Corp's last 12-month ROIC - WACC is 4.8%, based on the financial report for Dec 31, 2024 (Q4’2024). The average annual ROIC - WACC for Amgen Inc. have been 8.6% over the past three years, and 11.1% over the past five years.
2) Is Amgen Inc.'s ROIC - WACC Good?
As of today, Amgen Inc.'s ROIC - WACC is 4.8%, which is lower than industry median of 6.4%. It indicates that Amgen Inc.'s ROIC - WACC is Bad.